Sir Richard is Chairman of The Royal Institution of Great Britain and also Vice-Chairman at Swiss life sciences company Lonza Group. He remains Chairman of The UK Stem Cell Foundation, Chairman of the Careers Research and Advisory Centre (CRAC), Non-Executive Chairman of Circassia Holdings Ltd, Non-Executive Chairman of Omnicyte Ltd, Executive Chairman of Toumaz Holdings plc and is an Advisory member of Siemens Holdings plc and the Virgin Group Advisory Board. Prior to that, he was Senior Independent Director, Non-Executive Deputy Chairman and Chairman of the Remuneration Committee of ENRC from 2007 – June 2011, Chairman of NHS London from December 2008 to July 2010, Rector of Imperial College London from 2000 – 2008 and the Senior Independent Director of Rio Tinto plc from 1997 to 2008. He has over 30 years of experience within the biotechnology and pharmaceutical industries, serving as Chief Executive and Chairman of GlaxoWellcome from 1995 to 2000 and then as Chairman of GlaxoSmithkline until 2002.

Internationally, he is Chairman of the International Advisory Board, A*Star Biomedical Research Council, Singapore and a Board member of EDBI. He was awarded Honorary Citizenship of Singapore in 2004 for his contribution to the development of the country's biomedical sciences industry.

Sir Richard holds a number of degrees and awards from institutions both in the UK and overseas. He is a Fellow of the Royal Society and Academy of Medical Sciences, and Honorary Fellow of the Royal Academy of Engineering, Royal Society of Chemistry, Royal Pharmaceutical Society, Royal College of Pathologists and Royal College of Physicians. He is also President of the R&D Society, a position he has held since July 2002.

He is a Fellow of Imperial College London and Imperial College School of Medicine, King's College London and Honorary Fellow of the University of Wales, Cardiff and the University of Central Lancashire.

Sir Richard received a Knighthood in the 1994 New Year's Honours list for services to the pharmaceutical industry.

Jon Moulton, Chairman of Better Capital, was until recently Managing Partner of Alchemy, a UK-based private equity firm, which invested £2.0 billion of equity with an emphasis on dealing with troubled companies.  Alchemy also has a £300m European special opportunities fund investing principally in distressed debt.

He is a Chartered Accountant, a CF and Fellow of the Institute for Turnaround Professionals.  He previously worked with Citicorp Venture Capital in New York and London, Permira and Apax, where he has invested in a large variety of businesses including Life Sciences.  As well as having been a director of numerous companies and was also formerly Chairman of the British Allergy Foundation.

Lord Robert Winston is the first Professor of Science and Society at Imperial College London, a university with one of the strongest international science bases, where he will focus on the crucial importance of improving communication and public engagement with science. Concentrating on advancing the understanding and interaction between scientists and the public through a range of initiatives that will include conducting research into the most effective methods of science engagement and evaluating its impact, he will be using his experience and contacts to co-ordinate and build on existing outreach activity, establishing a dedicated schools laboratory and seminar facility based at the College to give pupils and teachers experience of hands-on science in areas such as DNA analysis and robotics.

He has around 300 scientific publications in peer-review journals on reproduction and embryology. He is also Chancellor of Sheffield Hallam University, Chairman of the Royal College of Music and was voted "Peer of the Year" by his fellow Parliamentarians in June 2008 for his expertise and work on the Human Fertilisation and Embryology Bill. Robert Winston is an Honorary Fellow of the Royal Academy of Engineering, a Fellow of the Academy of Medical Sciences, an Honorary Fellow of Queen Mary College, and holds honorary Fellowships of the Institute of Biology, the Royal College of Surgeons of Edinburgh and the Royal College of Physicians and Surgeons of Glasgow. He has been awarded honorary doctorates at nineteen universities.

Mary Archer has been chairman of Cambridge University Hospitals NHS Foundation Trust since 2002.  She is also convenor of the UK University Hospitals Chairs Group, a trustee of Addenbrooke’s Charitable Trust and CRAC, and a non-executive director of the Britten Sinfonia. She read Chemistry at St. Anne’s College, Oxford and obtained her PhD in Physical Chemistry from Imperial College, London.  After post-doctoral work at St. Hilda’s College, Oxford and the Royal Institution, London, she moved to Cambridge and for ten years taught chemistry for Newnham and Trinity Colleges. She is President of the UK Solar Energy Society, the Guild of Church Musicians and the Sinfonia of Cambridge.  She is the author of Rupert Brooke and The Old Vicarage, Grantchester (1989), and co-editor of Clean Electricity from Photovoltaics (2001), Molecular to Global Photosynthesis (2004), Nanostructured and Photoelectrochemical Systems for Solar Photon Conversion (2008) and The 1702 Chair of Chemistry at Cambridge (2005).  In June 2002, she was awarded the Melchett Medal by the Energy Institute, and in 2007 the Eva Philbin Award of the Institute of Chemistry of Ireland.

Nick Ross is a broadcaster who specialises in factual programmes from news and politics to consumer affairs and debates but is best-known for Crimewatch with he fronted for over 23 years. He is a psychologist by background, a Trustee of Sense About Science and a former member of the Committee on the Understanding of Science and twice Chairman of the Science Book Prize. He is President of HealthWatch, a charity devoted to promoting evidence-based medicine and health policy, and for 20 years has championed scientific methodology in many areas of social policy.

He is a member of several national bioethics committees and inquiries, was a Trustee of the Health Quality Service and has served on numerous government advisory boards including the Gene Therapy Advisory Committee. He founded the Jill Dando Institute of Crime Science at University College London where he is an honorary fellow and visiting professor, has an honorary doctorate from Queen's University Belfast and is a Fellow of the Royal Society of Medicine.

Professor Jones is a Director of Allergan Inc. (USA) and Sigma Tau S.p.A (Italy). He is Chairman of the UK stem cell biotech company ReNeuron plc., the International CRO Synexus Ltd., a member of the Boards of NextPharma Technologies Ltd., SciClone Pharmaceuticals Inc. (USA), VeronaPharma plc. and Tecnogen S.p.A. He is a visiting professor at King's College, London and holds honorary degrees and Gold Medals from 6 universities.

From 1987-94, he was a main board director of The Wellcome Foundation, where he was responsible for R&D including the development of AZT, Zovirax, Lamictal, Malarone and other medicines. He is a founder member of the Geneva-based Public: Private Partnership, Medicines for Malaria Venture (MMV), and in 2004 was appointed to the World Health Organisation (WHO) Commission on Intellectual Property Rights, Innovation and Public Health (C.I.P.I.H). He was for 12 years a member of The UK Government regulatory agency The Medicines Commission. For 10 years, until September 2004, he was Director General of the Association of the British Pharmaceutical Industry (ABPI) a member of Council of IFPMA and the Board of EFPIA.

In 2005 he was the winner of the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry.

He was honoured by Her Majesty Queen Elizabeth II by the award of CBE in the 2003 New Year's Honours List.

Steve Jones is Professor of Genetics at University College London, President of the Galton Institute, a Trustee of the Charles Darwin Foundation and a board member of the Learning Centre London. He was awarded the Royal Society Faraday Medal for the Public Understanding of Science in 1997.

Professor Jones is particularly concerned with school and public education and has written several books including The Cambridge Encyclopaedia of Human Evolution 1992; Y:The Descent of Men, 2002 and most recently The Single Helix: a Turn around the World of Science, 2005. He gave the 1991 Reith Lectures on ‘The Language of Genes’, presented the BBC TV series ‘In the Blood’ and has a regular column about science matters in the Daily Telegraph.

Professor Chris Mason is internationally recognized to be at the forefront of the emerging field of stem cell and regenerative medicine translation and commercialization. A background in basic science, clinical medicine, bioprocessing and business allows Chris a unique insight and understanding of the challenges facing the regenerative medicine sector as it grows into a competitive and sustainable global healthcare industry.

Chris holds a Clinical Sciences degree from Imperial College London, a Medical Degree from the United Medical and Dental Schools of Guy’s and St. Thomas’s Hospitals (now King’s College London) and a PhD under the supervision of Professor Peter Dunnill in tissue-engineering bioprocessing from University College London.

After graduating, he specialized in surgery and is a Fellow of the Royal College of Surgeons both of England and in Ireland. Today, after a transition from clinical practice to translational research, he heads up the Regenerative Medicine Bioprocess Group in the UCL Advanced Centre for Biochemical Engineering and is on the Steering Committee for the UCL Centre for Stem Cells & Regenerative Medicine. Other responsibilities include being Senior Editor of "Regenerative Medicine" journal, and co-founder and co-organiser of the London Regenerative Medicine Network (LRMN) – the world’s first and largest regenerative medicine network.

Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell therapies and tissue engineering; including membership of the ISSCR Industry Committee, the Alliance for Regenerative Medicine (ARM) Communication & Education Committee and the BIA Regenerative Medicine Industry Group. He also has a broad range of expertise in commercial consultancy and is presently on the Scientific Advisory Boards of a number of companies based in North America.